Provider review, September 2026
Zeuss carries a February 2026 federal warning letter for false and misleading claims, addressed to the company at the email address on this very site. It sells GHK-Cu only inside a three-ingredient hair formula, so it publishes no copper-peptide price at all.
Zeuss does not publish a price today.
Zeuss also sells 1 compound this site boards without publishing a price for it: GHK-Cu.
Zeuss is not a paid partner; this link may earn a commission if that changes. Full disclosure.
A warning letter issued in February 2026 names Zeuss LLC, trading as Zeuss, and is categorised as false and misleading claims and misbranding in a telehealth context.
It is attached to this record on the entity, not on a coincidence of names. The letter's recipient block carries the support address at this domain, and its opening line says the agency reviewed the website content at this site's own web address.
The company was then queried for siblings in the same federal table. It appears once, and no other seller on this roster matches it.
Both hair formulas Zeuss sells list a copper peptide alongside two other actives, with each ingredient's strength printed.
No price is recorded against GHK-Cu for that reason. A three-drug formula's figure filed under one of its ingredients would put a number on the copper-peptide board that this seller never attached to copper peptide.
The compound is still declared, because the seller genuinely dispenses it. What is absent is a price scoped to it.
Zeuss states that compounded medications have not been approved by the FDA and that the agency does not verify the safety, effectiveness or quality of compounded drugs.
It names Zeuss LLC as the operating company in its own terms, repeatedly, which makes the entity checkable.
It offers a full refund if a physician cannot prescribe treatment, and prints the milligram strength of every ingredient in its formulas.
No list of served states is published.
No dispensing pharmacy is named and no certificate of analysis is reachable.
A warning letter is not a finding about the drug a patient receives. It is a finding about what a company said, and it is on the public record either way.
Zeuss received an FDA warning letter issued February 2026. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.
Auren Rx names both its prescribing group, Wasef Health, and its dispensing pharmacy, VialsRX in Houston, with street addresses and phone numbers, and lets a subscriber pause an auto-refill plan on NAD+, sermorelin, glutathione or GHK-Cu instead of forcing a full cancellation.
Auren Rx is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Visit Auren RxIt is categorised as false and misleading claims and misbranding, in a telehealth context, and was issued in February 2026. It concerns what the company published, not a defect found in a specific medicine.
Yes. The letter's recipient block carries this site's own support email address, and its opening line names this site's web address as the content the agency reviewed.
Because every figure Zeuss publishes buys a formula containing a copper peptide plus two other actives. Filing that number under GHK-Cu would misdescribe what the money buys.
It does not say that. This letter is about claims and labelling. It is a matter of public record and worth knowing; it is not a finding about what arrives in the box.
Zeuss is not a paid partner; this link may earn a commission if that changes. Full disclosure.